The COVID-19 pandemic showed the world the threat that viruses can pose to both human health and the global economy. The WHO predicts further emergence of new human pathogens with epidemic potential and therefore the continued threat from viruses remains.
Climate change is also causing altered patterns of insect distributions leading to new human exposure to arboviruses – those spread by arthropods, like ticks and mosquitos – and intensive farming means the potential for animal to human infection (zoonosis) is increasing too.
Our aim is to improve patient lives by helping to overcome unmet translational needs in EVT, with a focus in low- and middle-income countries. This will include work on addressing the continued threat from established viruses (often referred to as ‘endemic’) such as flaviviruses, and others with epidemic or outbreak potential.
As part of our investment in Global Health, which will total more than £100 million, LifeArc is currently working with established organisations to determine our strategy and investments in this area, which could include scientific focus on:
- New therapeutics (particularly monoclonal antibodies or novel modalities)
- Low-cost diagnostics (including prognostic biomarkers)
- Addressing data gaps
- Supporting sustainable capacity building in the EVT ecosystem (including considerations of both accessibility and affordability).
If you work in EVT research or pandemic preparedness and would like to discuss more with us, please use the form below to get in touch.